Lunit and Labcorp Partner to Transform Tumor Microenvironment Analysis with AI-Powered Digital Pathology

Lunit and Labcorp announced a strategic collaboration on November 17, 2025, to advance AI-powered digital pathology research focused on oncology.1 2 5 6

The partnership leverages Labcorp’s clinical and pathology expertise together with Lunit’s advanced AI algorithms to transform analysis and interpretation of the tumor microenvironment, using techniques like high-resolution whole-slide imaging and AI-driven spatial profiling.1 6 5

Their initial collaborative studies were presented at the Society for Immunotherapy of Cancer (SITC) and Association for Molecular Pathology (AMP) conferences in November 2025.1 3

A key study demonstrated that Lunit’s AI could classify immune-active subtypes and predict therapy response for non-small cell lung cancers (NSCLC) with different MET gene alterations, such as exon 14 skipping and amplification.1 4

AI-based spatial profiling revealed inflamed tumor phenotypes associated with MET exon 14 skipping, often linked to better immunotherapy outcomes, and immune-desert phenotypes in MET-amplified tumors.1 4

Immune gene expression validation supported the accuracy of the AI-based immune phenotyping, suggesting the approach's utility for enhancing biomarker discovery and guiding personalized treatment decisions.1 4

Both companies aim to broaden their collaboration to apply digital pathology AI to additional cancer types and genomic contexts.1

Lunit SCOPE IO® and SCOPE uIHC, the AI tools behind these studies, are used to characterize tumor-immune interactions and identify predictive and therapeutic targets.3

The collaboration seeks to accelerate the integration of AI-powered digital pathology into both research paradigms and real-world clinical oncology practice.1 2 5 6